BioSpace News Archive

What percentage of a population needs to be immune in order to achieve herd immunity is a matter of debate among scientists and public health officials.

Beijing-based CRMO Pharmaron has accomplished impressive global growth via acquisitions over the past eight months.

This approval marks the first treatment indicated for reducing mortality risk in patients with the rare disorder known as molybdenum cofactor deficiency (MoCD) Type A.

Suzhou Medilink Therapeutics (Medilink), based in Suzhou, China, closed on a $50 million Series A financing round. An A1 series round was led by Apricot Capital and a series-A1 was co-led by Loyal Valley Capital and Qiming Venture Partners.

On Sunday, Reuters reported the U.K. pharma giant sold off its 7.7% stake in the company for more than $1 billion.

Merck KGaA, Darmstadt, Germany plunked down €188 million (about $226 million) in upfront cash to acquire exclusive global development and commercialization rights to Debiopharm’s oral Inhibitor of Apoptosis Proteins (IAP) antagonist, xevinapant.

Vetex Medical Ltd. today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the ReVene® Thrombectomy Catheter. ReVene uses dual-action technology designed to de-clot peripheral vessels, such as in Deep Vein Thrombosis (DVT), through wall-to-wall contact in a single session without the use of thrombolytics.

Series C round led by RTW Investments, LP; RA Capital Management; Fidelity Management & Research Company; and funds and accounts advised by T. Rowe Price Associates, Inc.; and joined by existing investors including The Column Group, Casdin Capital and GV. Funds will help advance lead gene therapy program in hypertrophic cardiomyopathy (HCM) as well as multiple programs across three therapeutic platforms: Gene Therapy,

Maine’s Largest Statewide Physician-Owned Multispecialty Adopts Integrated Ambulatory Platform to Improve Patient-Provider Experience and Financial Outcomes

Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity.